Leibowitz Akiva, Brotfain Evgeni, Koyfman Leonid, Klein Moti, Hess Shmuel, Zlotnik Alexander, Boyko Matthew
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Department of Anesthesiology and Critical Care, General Intensive Care Unit, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Eur J Trauma Emerg Surg. 2019 Apr;45(2):263-271. doi: 10.1007/s00068-018-0908-9. Epub 2018 Jan 17.
Treatment of combined traumatic brain injury and hemorrhagic shock, poses a particular challenge due to the possible conflicting consequences. While restoring diminished volume is the treatment goal for hypovolemia, maintaining adequate cerebral perfusion pressure and avoidance of secondary damage remains a treatment goal for the injured brain. Various treatment modalities have been proposed, but the optimal resuscitation fluid and goals have not yet been clearly defined. A growing body of evidence suggests that in hypovolemic shock, resuscitation with fresh whole blood (FWB) may be superior to component therapy without platelets (which are likely to be unavailable in the pre-hospital setting). Nevertheless, the effects of this approach have not been studied in the combined injury. Previously, in a rat model of combined injury we have found that mild resuscitation to MABP of 80 mmHg with FWB is superior to fluid resuscitation or aggressive resuscitation with FWB. In this study, we investigate the physiological and neurological outcomes in a rat model of combined traumatic brain injury (TBI) and hypovolemic shock, submitted to treatment with varying amounts of FWB, compared to similar resuscitation goals with fractionated blood products-red blood cells (RBCs) and plasma in a 1:1 ratio regimen.
40 male Lewis rats were divided into control and treatment groups. TBI was inflicted by a free-falling rod on the exposed cranium. Hypovolemia was induced by controlled hemorrhage of 30% blood volume. Treatment groups were treated either with fresh whole blood or with RBC + plasma in a 1:1 ratio, achieving a resuscitation goal of a mean arterial blood pressure (MAP) of 80 mmHg at 15 min. MAP was assessed at 60 min, and neurological outcomes and mortality in the subsequent 24 h.
At 60 min, hemodynamic parameters were improved compared to controls, but not significantly different between treatment groups. Survival rates at 48 h were 100% for both of the mildly resuscitated groups (MABP 80 mmHg) with FWB and RBC + plasma. The best neurological outcomes were found in the group mildly resuscitated with FWB and were better when compared to resuscitation with RBC + plasma to the same MABP goal (FWB: Neurological Severity Score (NSS) 6 ± 2, RBC + plasma: NSS 10 ± 2, p = 0.02).
In this study, we find that mild resuscitation with goals of restoring MAP to 80 mmHg (which is lower than baseline) with FWB, provided better hemodynamic stability and survival. However, the best neurological outcomes were found in the group resuscitated with FWB. Thus, we suggest that resuscitation with FWB is a feasible modality in the combined TBI + hypovolemic shock scenario, and may result in improved outcomes compared to platelet-free component blood products.
创伤性脑损伤合并失血性休克的治疗面临特殊挑战,因为可能存在相互矛盾的后果。虽然恢复减少的血容量是治疗低血容量的目标,但维持足够的脑灌注压并避免继发性损伤仍是受伤大脑的治疗目标。已经提出了各种治疗方式,但最佳的复苏液体和目标尚未明确界定。越来越多的证据表明,在低血容量性休克中,用新鲜全血(FWB)复苏可能优于无血小板的成分治疗(在院前环境中可能无法获得血小板)。然而,这种方法在合并损伤中的效果尚未得到研究。此前,在一个合并损伤的大鼠模型中,我们发现用FWB将平均动脉血压(MABP)轻度复苏至80mmHg优于液体复苏或用FWB进行积极复苏。在本研究中,我们调查了创伤性脑损伤(TBI)合并低血容量性休克大鼠模型的生理和神经学结局,该模型接受不同量的FWB治疗,并与采用1:1比例的红细胞(RBC)和血浆成分输血达到类似复苏目标的情况进行比较。
40只雄性Lewis大鼠分为对照组和治疗组。通过将自由落体杆撞击暴露的颅骨造成TBI。通过控制出血30%血容量诱导低血容量。治疗组分别用新鲜全血或1:1比例的RBC + 血浆进行治疗,在15分钟时实现平均动脉血压(MAP)为80mmHg的复苏目标。在60分钟时评估MAP,并在随后的24小时内评估神经学结局和死亡率。
与对照组相比,60分钟时血流动力学参数有所改善,但治疗组之间无显著差异。用FWB和RBC + 血浆进行轻度复苏(MABP 80mmHg)的两组在48小时时的存活率均为100%。用FWB轻度复苏的组神经学结局最佳,与达到相同MABP目标的RBC + 血浆复苏相比更好(FWB:神经严重程度评分(NSS)6±2,RBC + 血浆:NSS 10±2,p = 0.02)。
在本研究中,我们发现用FWB将MAP恢复至80mmHg(低于基线)的轻度复苏提供了更好的血流动力学稳定性和存活率。然而,用FWB复苏的组神经学结局最佳。因此,我们建议在TBI + 低血容量性休克合并情况下,用FWB复苏是一种可行的方式,与无血小板的成分血制品相比可能会改善结局。